TY - JOUR
T1 - Extracellular vesicles-transferred SBSN drives glioma aggressiveness by activating NF-κB via ANXA1-dependent ubiquitination of NEMO
AU - Chen, Han
AU - Chen, Xuhong
AU - Zhang, Zhuojun
AU - Bao, Wenhao
AU - Gao, Zhiqing
AU - Li, Difeng
AU - Xie, Xiaoyi
AU - Zhou, Ping
AU - Yang, Chunxiao
AU - Zhou, Zhongqiu
AU - Pan, Jinyuan
AU - Kuang, Xiangqin
AU - Tang, Ruiming
AU - Feng, Zhengfu
AU - Zhou, Lihuan
AU - Zhu, Dachun
AU - Yang, Jianan
AU - Wang, Lan
AU - Huang, Hongbiao
AU - Tang, Daolin
AU - Liu, Jinbao
AU - Jiang, Lili
N1 - Funding Information:
This work was supported by the Basic and Applied Research Projects of Guangzhou Science and Technology Bureau (202002030067), the Natural Science Foundation of China (82273464, 81972619, 81672874, and 81972399), the Natural Science Foundation of Guangdong Province (2021A1515012477 and 2022A1515012260), the Key Discipline of Guangzhou Education Bureau (Basic Medicine) (201851839), the Natural Science Foundation research team of Guangdong Province (2018B030312001), the open research funds from the Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital (202011-202), the Innovative Academic Team of Guangzhou Education System (1201610014), and the Guangzhou key medical discipline construction project fun.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/12/2
Y1 - 2022/12/2
N2 - Glioma is the most common malignant primary brain tumor with aggressiveness and poor prognosis. Although extracellular vesicles (EVs)-based cell-to-cell communication mediates glioma progression, the key molecular mediators of this process are still not fully understood. Herein, we elucidated an EVs-mediated transfer of suprabasin (SBSN), leading to the aggressiveness and progression of glioma. High levels of SBSN were positively correlated with clinical grade, predicting poor clinical prognosis of patients. Upregulation of SBSN promoted, while silencing of SBSN suppressed tumorigenesis and aggressiveness of glioma cells in vivo. EVs-mediated transfer of SBSN resulted in an increase in SBSN levels, which promoted the aggressiveness of glioma cells by enhancing migration, invasion, and angiogenesis of recipient glioma cells. Mechanistically, SBSN activated NF-κB signaling by interacting with annexin A1, which further induced Lys63-linked and Met1-linear polyubiquitination of NF-κB essential modulator (NEMO). In conclusion, the communication of SBSN-containing EVs within glioma cells drives the formation and development of tumors by activating NF-κB pathway, which may provide potential therapeutic target for clinical intervention in glioma.
AB - Glioma is the most common malignant primary brain tumor with aggressiveness and poor prognosis. Although extracellular vesicles (EVs)-based cell-to-cell communication mediates glioma progression, the key molecular mediators of this process are still not fully understood. Herein, we elucidated an EVs-mediated transfer of suprabasin (SBSN), leading to the aggressiveness and progression of glioma. High levels of SBSN were positively correlated with clinical grade, predicting poor clinical prognosis of patients. Upregulation of SBSN promoted, while silencing of SBSN suppressed tumorigenesis and aggressiveness of glioma cells in vivo. EVs-mediated transfer of SBSN resulted in an increase in SBSN levels, which promoted the aggressiveness of glioma cells by enhancing migration, invasion, and angiogenesis of recipient glioma cells. Mechanistically, SBSN activated NF-κB signaling by interacting with annexin A1, which further induced Lys63-linked and Met1-linear polyubiquitination of NF-κB essential modulator (NEMO). In conclusion, the communication of SBSN-containing EVs within glioma cells drives the formation and development of tumors by activating NF-κB pathway, which may provide potential therapeutic target for clinical intervention in glioma.
UR - http://www.scopus.com/inward/record.url?scp=85140968174&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140968174&partnerID=8YFLogxK
U2 - 10.1038/s41388-022-02520-6
DO - 10.1038/s41388-022-02520-6
M3 - Article
C2 - 36316443
AN - SCOPUS:85140968174
SN - 0950-9232
VL - 41
SP - 5253
EP - 5265
JO - Oncogene
JF - Oncogene
IS - 49
ER -